XML 54 R37.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Supplemental Guarantor Financial Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract] |
Condensed Consolidating Income and Comprehensive Income Statements | HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Year Ended December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 679.2 |  |  | $ | 306.9 |  |  | $ | (374.5 | ) |  | $ | 611.6 |
Cost of products sold | — |  |  | 385.7 |  |  | 263.5 |  |  | (374.5 | ) |  | 274.7 |
Gross Profit | — |  |  | 293.5 |  |  | 43.4 |  |  | — |  |  | 336.9 |
Research and development expenses | — |  |  | 38.2 |  |  | — |  |  | — |  |  | 38.2 |
Selling and general expenses | 29.9 |  |  | 249.7 |  |  | 42.1 |  |  | — |  |  | 321.7 |
Other expense (income), net | 0.7 |  |  | 34.5 |  |  | (15.1 | ) |  | — |  |  | 20.1 |
Operating (Loss) Profit | (30.6 | ) |  | (28.9 | ) |  | 16.4 |  |  | — |  |  | (43.1 | )
Interest income | 0.9 |  |  | 0.1 |  |  | 4.5 |  |  | (3.0 | ) |  | 2.5 |
Interest expense | (32.3 | ) |  | (2.2 | ) |  | (0.1 | ) |  | 3.0 |  |  | (31.6 | )
(Loss) Income Before Income Taxes | (62.0 | ) |  | (31.0 | ) |  | 20.8 |  |  | — |  |  | (72.2 | )
Income tax benefit (provision) | 20.0 |  |  | 23.2 |  |  | (3.1 | ) |  | — |  |  | 40.1 |
Equity in earnings of consolidated subsidiaries | 125.1 |  |  | 32.6 |  |  | — |  |  | (157.7 | ) |  | — |
Net Income (Loss) from Continuing Operations | 83.1 |  |  | 24.8 |  |  | 17.7 |  |  | (157.7 | ) |  | (32.1 | )
(Loss) Income on discontinued operations, net of tax | (3.8 | ) |  | 86.0 |  |  | 29.2 |  |  | — |  |  | 111.4 |
Net Income (Loss) | 79.3 |  |  | 110.8 |  |  | 46.9 |  |  | (157.7 | ) |  | 79.3 |
Total other comprehensive income (loss), net of tax | 18.8 |  |  | 13.1 |  |  | 18.3 |  |  | (31.4 | ) |  | 18.8 |
Comprehensive Income (Loss) | $ | 98.1 |  |  | $ | 123.9 |  |  | $ | 65.2 |  |  | $ | (189.1 | ) |  | $ | 98.1 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Year Ended December 31, 2016
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 625.4 |  |  | $ | 250.0 |  |  | $ | (309.2 | ) |  | $ | 566.2 |
Cost of products sold | — |  |  | 356.7 |  |  | 221.5 |  |  | (309.2 | ) |  | 269.0 |
Gross Profit | — |  |  | 268.7 |  |  | 28.5 |  |  | — |  |  | 297.2 |
Research and development expenses | — |  |  | 38.0 |  |  | 0.4 |  |  | — |  |  | 38.4 |
Selling and general expenses | 37.2 |  |  | 274.2 |  |  | 34.8 |  |  | — |  |  | 346.2 |
Other (income) expense, net | (0.8 | ) |  | 36.4 |  |  | (17.5 | ) |  | 1.6 |  |  | 19.7 |
Operating (Loss) Profit | (36.4 | ) |  | (79.9 | ) |  | 10.8 |  |  | (1.6 | ) |  | (107.1 | )
Interest income | 0.3 |  |  | 0.1 |  |  | 2.5 |  |  | (2.3 | ) |  | 0.6 |
Interest expense | (33.1 | ) |  | (1.7 | ) |  | (0.2 | ) |  | 2.3 |  |  | (32.7 | )
(Loss) Income Before Income Taxes | (69.2 | ) |  | (81.5 | ) |  | 13.1 |  |  | (1.6 | ) |  | (139.2 | )
Income tax benefit (provision) | 25.5 |  |  | 33.9 |  |  | (3.5 | ) |  | — |  |  | 55.9 |
Equity in earnings of consolidated subsidiaries | 85.3 |  |  | 22.3 |  |  | — |  |  | (107.6 | ) |  | — |
Income (Loss) from Continued Operations | 41.6 |  |  | (25.3 | ) |  | 9.6 |  |  | (109.2 | ) |  | (83.3 | )
(Loss) Income from discontinued operations, net of tax | (1.8 | ) |  | 108.6 |  |  | 16.3 |  |  | — |  |  | 123.1 |
Net Income (Loss) | 39.8 |  |  | 83.3 |  |  | 25.9 |  |  | (109.2 | ) |  | 39.8 |
Total other comprehensive loss, net of tax | (6.9 | ) |  | (6.3 | ) |  | (7.2 | ) |  | 13.5 |  |  | (6.9 | )
Comprehensive Income | $ | 32.9 |  |  | $ | 77.0 |  |  | $ | 18.7 |  |  | $ | (95.7 | ) |  | $ | 32.9 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED COMBINED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Year Ended December 31, 2015
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 591.2 |  |  | $ | 266.4 |  |  | $ | (348.6 | ) |  | $ | 509.0 |
Cost of products sold | — |  |  | 338.8 |  |  | 261.0 |  |  | (348.6 | ) |  | 251.2 |
Gross Profit | — |  |  | 252.4 |  |  | 5.4 |  |  | — |  |  | 257.8 |
Research and development expenses | — |  |  | 27.6 |  |  | — |  |  | — |  |  | 27.6 |
Selling and general expenses | 30.6 |  |  | 274.4 |  |  | 44.7 |  |  | — |  |  | 349.7 |
Other (income) expense, net | (0.8 | ) |  | 26.9 |  |  | (9.9 | ) |  | — |  |  | 16.2 |
Operating Loss | (29.8 | ) |  | (76.5 | ) |  | (29.4 | ) |  | — |  |  | (135.7 | )
Interest income | 0.3 |  |  | — |  |  | 3.1 |  |  | (3.1 | ) |  | 0.3 |
Interest expense | (33.8 | ) |  | (2.1 | ) |  | (0.3 | ) |  | 3.1 |  |  | (33.1 | )
Loss Before Income Taxes | (63.3 | ) |  | (78.6 | ) |  | (26.6 | ) |  | — |  |  | (168.5 | )
Income tax benefit (provision) | 24.3 |  |  | 44.7 |  |  | (1.7 | ) |  | — |  |  | 67.3 |
Equity in (loss) earnings of consolidated subsidiaries | (389.5 | ) |  | 22.4 |  |  | — |  |  | 367.1 |  |  | — |
(Loss) Income from Continued Operations | (428.5 | ) |  | (11.5 | ) |  | (28.3 | ) |  | 367.1 |  |  | (101.2 | )
Income (Loss) from discontinued operations, net of tax | 2.2 |  |  | (366.4 | ) |  | 39.1 |  |  | — |  |  | (325.1 | )
Net (Loss) Income | (426.3 | ) |  | (377.9 | ) |  | 10.8 |  |  | 367.1 |  |  | (426.3 | )
Total other comprehensive loss, net of tax | — |  |  | (0.1 | ) |  | (24.0 | ) |  | — |  |  | (24.1 | )
Comprehensive (Loss) Income | $ | (426.3 | ) |  | $ | (378.0 | ) |  | $ | (13.2 | ) |  | $ | 367.1 |  |  | $ | (450.4 | )
Condensed Consolidating Balance Sheets | HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 114.5 |  |  | $ | 16.0 |  |  | $ | 89.2 |  |  | $ | — |  |  | $ | 219.7 |
Accounts receivable, net | 1.1 |  |  | 623.0 |  |  | 266.3 |  |  | (687.4 | ) |  | 203.0 |
Inventories | — |  |  | 76.0 |  |  | 15.1 |  |  | — |  |  | 91.1 |
Prepaid and other current assets | 0.6 |  |  | 11.7 |  |  | 2.1 |  |  | — |  |  | 14.4 |
Assets held for sale | 0.3 |  |  | 546.7 |  |  | 85.5 |  |  | — |  |  | 632.5 |
Total Current Assets | 116.5 |  |  | 1,273.4 |  |  | 458.2 |  |  | (687.4 | ) |  | 1,160.7 |
Property, Plant and Equipment, Net | — |  |  | 92.9 |  |  | 17.0 |  |  | — |  |  | 109.9 |
Investment in Consolidated Subsidiaries | 2,154.3 |  |  | 403.2 |  |  | — |  |  | (2,557.5 | ) |  | — |
Goodwill | — |  |  | 738.1 |  |  | 26.6 |  |  | — |  |  | 764.7 |
Other Intangible Assets, net | — |  |  | 139.5 |  |  | 9.4 |  |  | — |  |  | 148.9 |
Other Assets | 0.3 |  |  | 6.0 |  |  | 5.4 |  |  | — |  |  | 11.7 |
TOTAL ASSETS | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Current portion of long-term debt | $ | 39.8 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 39.8 |
Trade accounts payable | 454.0 |  |  | 347.0 |  |  | 49.8 |  |  | (679.6 | ) |  | 171.2 |
Accrued expenses | 11.6 |  |  | 113.9 |  |  | 27.4 |  |  | (8.0 | ) |  | 144.9 |
Liabilities held for sale | — |  |  | 7.8 |  |  | 26.1 |  |  | — |  |  | 33.9 |
Total Current Liabilities | 505.4 |  |  | 468.7 |  |  | 103.3 |  |  | (687.6 | ) |  | 389.8 |
Long-Term Debt | 541.1 |  |  | — |  |  | — |  |  | — |  |  | 541.1 |
Other Long-Term Liabilities | 9.2 |  |  | 36.1 |  |  | 4.3 |  |  | — |  |  | 49.6 |
Total Liabilities | 1,055.7 |  |  | 504.8 |  |  | 107.6 |  |  | (687.6 | ) |  | 980.5 |
Total Equity | 1,215.4 |  |  | 2,148.3 |  |  | 409.0 |  |  | (2,557.3 | ) |  | 1,215.4 |
TOTAL LIABILITIES AND EQUITY | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of December 31, 2016
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 54.2 |  |  | $ | 9.5 |  |  | $ | 50.0 |  |  | $ | — |  |  | $ | 113.7 |
Accounts receivable, net | 3.1 |  |  | 552.5 |  |  | 239.9 |  |  | (607.0 | ) |  | 188.5 |
Inventories | — |  |  | 69.2 |  |  | 11.5 |  |  | — |  |  | 80.7 |
Prepaid and other current assets | 5.0 |  |  | 10.1 |  |  | 1.8 |  |  | (0.3 | ) |  | 16.6 |
Assets held for sale | — |  |  | 162.3 |  |  | 31.7 |  |  | — |  |  | 194.0 |
Total Current Assets | 62.3 |  |  | 803.6 |  |  | 334.9 |  |  | (607.3 | ) |  | 593.5 |
Property, Plant and Equipment, Net | — |  |  | 96.7 |  |  | 12.6 |  |  | — |  |  | 109.3 |
Investment in Consolidated Subsidiaries | 2,029.5 |  |  | 328.7 |  |  | — |  |  | (2,358.2 | ) |  | — |
Goodwill | — |  |  | 736.1 |  |  | 26.2 |  |  | — |  |  | 762.3 |
Other Intangible Assets, net | — |  |  | 159.5 |  |  | 8.7 |  |  | — |  |  | 168.2 |
Other Assets | 0.7 |  |  | 7.7 |  |  | 3.2 |  |  | — |  |  | 11.6 |
Assets Held for Sale | 0.3 |  |  | 380.0 |  |  | 46.6 |  |  | — |  |  | 426.9 |
TOTAL ASSETS | $ | 2,092.8 |  |  | $ | 2,512.3 |  |  | $ | 432.2 |  |  | $ | (2,965.5 | ) |  | $ | 2,071.8 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Trade accounts payable | $ | 398.3 |  |  | $ | 325.9 |  |  | $ | 38.3 |  |  | $ | (601.9 | ) |  | $ | 160.6 |
Accrued expenses | 11.1 |  |  | 108.5 |  |  | 24.2 |  |  | (5.4 | ) |  | 138.4 |
Liabilities held for sale | — |  |  | 8.3 |  |  | 17.1 |  |  | — |  |  | 25.4 |
Total Current Liabilities | 409.4 |  |  | 442.7 |  |  | 79.6 |  |  | (607.3 | ) |  | 324.4 |
Long-Term Debt | 579.0 |  |  | — |  |  | — |  |  | — |  |  | 579.0 |
Other Long-Term Liabilities | 1.9 |  |  | 52.9 |  |  | 4.4 |  |  | — |  |  | 59.2 |
Liabilities Held for Sale | — |  |  | 1.5 |  |  | 5.2 |  |  | — |  |  | 6.7 |
Total Liabilities | 990.3 |  |  | 497.1 |  |  | 89.2 |  |  | (607.3 | ) |  | 969.3 |
Total Equity | 1,102.5 |  |  | 2,015.2 |  |  | 343.0 |  |  | (2,358.2 | ) |  | 1,102.5 |
TOTAL LIABILITIES AND EQUITY | $ | 2,092.8 |  |  | $ | 2,512.3 |  |  | $ | 432.2 |  |  | $ | (2,965.5 | ) |  | $ | 2,071.8 |
Condensed Consolidating Statements of Cash Flows | HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Year Ended December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (43.3 | ) |  | $ | 137.2 |  |  | $ | 50.3 |  |  | $ | — |  |  | $ | 144.2 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (32.4 | ) |  | (10.8 | ) |  | — |  |  | (43.2 | )
Proceeds from dispositions of property | — |  |  | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Intercompany contributions | — |  |  | (98.8 | ) |  | — |  |  | 98.8 |  |  | — |
Cash (Used in) Provided by Investing Activities | — |  |  | (131.1 | ) |  | (10.8 | ) |  | 98.8 |  |  | (43.1 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 101.4 |  |  | — |  |  | (2.6 | ) |  | (98.8 | ) |  | — |
Purchase of treasury stock | (2.5 | ) |  | — |  |  | — |  |  | — |  |  | (2.5 | )
Proceeds and excess tax benefits from the exercise of stock options | 4.7 |  |  | — |  |  | — |  |  | — |  |  | 4.7 |
Cash Provided by (Used in) Financing Activities | 103.6 |  |  | — |  |  | (2.6 | ) |  | (98.8 | ) |  | 2.2 |
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | 0.4 |  |  | 2.3 |  |  | — |  |  | 2.7 |
Increase in Cash and Cash Equivalents | 60.3 |  |  | 6.5 |  |  | 39.2 |  |  | — |  |  | 106.0 |
Cash and Cash Equivalents, Beginning of Period | 54.2 |  |  | 9.5 |  |  | 50.0 |  |  | — |  |  | 113.7 |
Cash and Cash Equivalents, End of Period | $ | 114.5 |  |  | $ | 16.0 |  |  | $ | 89.2 |  |  | $ | — |  |  | $ | 219.7 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Year Ended December 31, 2016
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (33.0 | ) |  | $ | 207.7 |  |  | $ | 15.8 |  |  | $ | (1.7 | ) |  | $ | 188.8 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (22.7 | ) |  | (6.4 | ) |  | — |  |  | (29.1 | )
Acquisition of business, net of cash acquired | (175.0 | ) |  | — |  |  | — |  |  | — |  |  | (175.0 | )
Proceeds from property dispositions | — |  |  | 3.2 |  |  | — |  |  | — |  |  | 3.2 |
Intercompany contributions | 0.5 |  |  | (177.9 | ) |  | 2.7 |  |  | 174.7 |  |  | — |
Cash (Used in) Provided by Investing Activities | (174.5 | ) |  | (197.4 | ) |  | (3.7 | ) |  | 174.7 |  |  | (200.9 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 170.8 |  |  | — |  |  | (0.3 | ) |  | (170.5 | ) |  | — |
Line of credit facility proceeds | 72.0 |  |  | — |  |  | — |  |  | — |  |  | 72.0 |
Line of credit facility repayments | (72.0 | ) |  | — |  |  | — |  |  | — |  |  | (72.0 | )
Debt issuance costs | (0.9 | ) |  | — |  |  | — |  |  | — |  |  | (0.9 | )
Purchase of treasury stock | (0.9 | ) |  | — |  |  | — |  |  | — |  |  | (0.9 | )
Proceeds and excess tax benefits from the exercise of stock options | 0.4 |  |  | — |  |  | — |  |  | — |  |  | 0.4 |
Cash Provided by (Used in) Financing Activities | 169.4 |  |  | — |  |  | (0.3 | ) |  | (170.5 | ) |  | (1.4 | )
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | (0.8 | ) |  | (1.5 | ) |  | — |  |  | (2.3 | )
(Decrease) Increase in Cash and Cash Equivalents | (38.1 | ) |  | 9.5 |  |  | 10.3 |  |  | 2.5 |  |  | (15.8 | )
Cash and Cash Equivalents, Beginning of Period | 92.3 |  |  | — |  |  | 39.7 |  |  | (2.5 | ) |  | 129.5 |
Cash and Cash Equivalents, End of Period | $ | 54.2 |  |  | $ | 9.5 |  |  | $ | 50.0 |  |  | $ | — |  |  | $ | 113.7 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED COMBINED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Year Ended December 31, 2015
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (44.7 | ) |  | $ | 110.5 |  |  | $ | 34.3 |  |  | $ | (2.5 | ) |  | $ | 97.6 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (61.3 | ) |  | (9.1 | ) |  | — |  |  | (70.4 | )
Proceeds from property dispositions | — |  |  | — |  |  | 7.8 |  |  | — |  |  | 7.8 |
Intercompany contributions | 39.9 |  |  | (53.1 | ) |  | 1.3 |  |  | 11.9 |  |  | — |
Cash Provided by (Used in) Investing Activities | 39.9 |  |  | (114.4 | ) |  | — |  |  | 11.9 |  |  | (62.6 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 46.5 |  |  | — |  |  | (34.6 | ) |  | (11.9 | ) |  | — |
Debt repayments | (51.0 | ) |  | — |  |  | — |  |  | — |  |  | (51.0 | )
Purchase of treasury stock | (1.0 | ) |  | — |  |  | — |  |  | — |  |  | (1.0 | )
Proceeds and excess tax benefits from the exercise of stock options | 1.4 |  |  | — |  |  | — |  |  | — |  |  | 1.4 |
Cash Used in Financing Activities | (4.1 | ) |  | — |  |  | (34.6 | ) |  | (11.9 | ) |  | (50.6 | )
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | — |  |  | (3.9 | ) |  | — |  |  | (3.9 | )
Decrease in Cash and Cash Equivalents | (8.9 | ) |  | (3.9 | ) |  | (4.2 | ) |  | (2.5 | ) |  | (19.5 | )
Cash and Cash Equivalents, Beginning of Period | 101.2 |  |  | 3.9 |  |  | 43.9 |  |  | — |  |  | 149.0 |
Cash and Cash Equivalents, End of Period | $ | 92.3 |  |  | $ | — |  |  | $ | 39.7 |  |  | $ | (2.5 | ) |  | $ | 129.5 |

X
- References No definition available. + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration